Literature DB >> 19293777

Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.

Mario Amendola1, Laura Passerini, Ferdinando Pucci, Bernhard Gentner, Rosa Bacchetta, Luigi Naldini.   

Abstract

RNA interference (RNAi) has tremendous potential for investigating gene function and developing new therapies. However, the design and validation of proficient vehicles for stable and safe microRNA (miR) and small interfering RNA (siRNA) delivery into relevant target cells remains an active area of investigation. Here, we developed a lentiviral platform to efficiently coexpress one or more natural/artificial miR together with a gene of interest from constitutive or regulated polymerase-II (Pol-II) promoters. By swapping the stem-loop (sl) sequence of a selected primary transcript (pri-miR) with that of other miR or replacing the stem with an siRNA of choice, we consistently obtained robust expression of the chimeric/artificial miR in several cell types. We validated our platform transducing a panel of engineered cells stably expressing sensitive reporters for miR activity and on a natural target. This approach allowed us to quantitatively assess at steady state the target suppression activity and expression level of each delivered miR and to compare it to those of endogenous miR. Exogenous/artificial miR reached the concentration and activity typical of highly expressed natural miR without perturbing endogenous miR maturation or regulation. Finally, we demonstrate the robust performance of the platform reversing the anergic/suppressive phenotype of human primary regulatory T cells (Treg) by knocking-down their master gene Forkhead Transcription Factor P3 (FOXP3).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293777      PMCID: PMC2835189          DOI: 10.1038/mt.2009.48

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

Review 1.  Tie receptors: new modulators of angiogenic and lymphangiogenic responses.

Authors:  N Jones; K Iljin; D J Dumont; K Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2001-04       Impact factor: 94.444

2.  High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors.

Authors:  P Salmon; V Kindler; O Ducrey; B Chapuis; R H Zubler; D Trono
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

3.  A system for Cre-regulated RNA interference in vivo.

Authors:  Patrick Stern; Sophie Astrof; Stefan J Erkeland; Joshua Schustak; Phillip A Sharp; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

4.  Lentiviral vectors for enhanced gene expression in human hematopoietic cells.

Authors:  A Ramezani; T S Hawley; R G Hawley
Journal:  Mol Ther       Date:  2000-11       Impact factor: 11.454

5.  Design of expression vectors for RNA interference based on miRNAs and RNA splicing.

Authors:  Guangwei Du; Joshua Yonekubo; Yue Zeng; Mary Osisami; Michael A Frohman
Journal:  FEBS J       Date:  2006-10-31       Impact factor: 5.542

6.  Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.

Authors:  O ter Brake; N Legrand; K J von Eije; M Centlivre; H Spits; K Weijer; B Blom; B Berkhout
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

7.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.

Authors:  A Follenzi; L E Ailles; S Bakovic; M Geuna; L Naldini
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

8.  Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs.

Authors:  L A Aagaard; J Zhang; K J von Eije; H Li; P Saetrom; M Amarzguioui; J J Rossi
Journal:  Gene Ther       Date:  2008-09-18       Impact factor: 5.250

9.  Posttranscriptional regulation of miRNAs harboring conserved terminal loops.

Authors:  Gracjan Michlewski; Sonia Guil; Colin A Semple; Javier F Cáceres
Journal:  Mol Cell       Date:  2008-11-07       Impact factor: 17.970

10.  Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development.

Authors:  Gwen Liu; Hyeyoung Min; Sibiao Yue; Chang-Zheng Chen
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

View more
  36 in total

Review 1.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

Review 2.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

3.  Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis.

Authors:  Chiu-Ling Chen; Jaw-Ching Wu; Guan-Yu Chen; Pei-Hsiang Yuan; Yen-Wen Tseng; Kuei-Chang Li; Shiaw-Min Hwang; Yu-Chen Hu
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

4.  A Lentiviral Fluorescent Genetic Barcoding System for Flow Cytometry-Based Multiplex Tracking.

Authors:  Tobias Maetzig; Jens Ruschmann; Courteney K Lai; Mor Ngom; Suzan Imren; Patricia Rosten; Gudmundur L Norddahl; Niklas von Krosigk; Lea Sanchez Milde; Christopher May; Anton Selich; Michael Rothe; Ishpreet Dhillon; Axel Schambach; R Keith Humphries
Journal:  Mol Ther       Date:  2017-01-05       Impact factor: 11.454

5.  A double-switch vector system positively regulates transgene expression by endogenous microRNA expression (miR-ON vector).

Authors:  Mario Amendola; Alice Giustacchini; Bernhard Gentner; Luigi Naldini
Journal:  Mol Ther       Date:  2013-02-26       Impact factor: 11.454

6.  Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.

Authors:  L D'Abundo; E Callegari; A Bresin; A Chillemi; B K Elamin; P Guerriero; X Huang; E Saccenti; E M A A Hussein; F Casciano; P Secchiero; G Zauli; G A Calin; G Russo; L J Lee; C M Croce; G Marcucci; S Sabbioni; F Malavasi; M Negrini
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

7.  Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells.

Authors:  Alessia Baccarini; Hemangini Chauhan; Thomas J Gardner; Anitha D Jayaprakash; Ravi Sachidanandam; Brian D Brown
Journal:  Curr Biol       Date:  2011-02-25       Impact factor: 10.834

8.  Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses.

Authors:  D Ivacik; A Ely; N Ferry; P Arbuthnot
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

9.  Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Authors:  Xiaomeng Huang; Sebastian Schwind; Bo Yu; Ramasamy Santhanam; Hongyan Wang; Pia Hoellerbauer; Alice Mims; Rebecca Klisovic; Alison R Walker; Kenneth K Chan; William Blum; Danilo Perrotti; John C Byrd; Clara D Bloomfield; Michael A Caligiuri; Robert J Lee; Ramiro Garzon; Natarajan Muthusamy; Ly James Lee; Guido Marcucci
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

10.  Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis.

Authors:  Lucia Cottone; Annalisa Capobianco; Chiara Gualteroni; Antonella Monno; Isabella Raccagni; Silvia Valtorta; Tamara Canu; Tiziano Di Tomaso; Angelo Lombardo; Antonio Esposito; Rosa Maria Moresco; Alessandro Del Maschio; Luigi Naldini; Patrizia Rovere-Querini; Marco E Bianchi; Angelo A Manfredi
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.